Impact of CDK4/6 inhibitors on health-related quality of life outcomes in patients with metastatic breast cancer: A systematic review and meta-analysis [0.03%]
CDK4/6抑制剂对转移性乳腺癌患者健康相关生活质量结局的影响：系统评价和Meta分析
Takako Kiener,Kevin H Li,Erin Chiang et al.
Takako Kiener et al.
Background: The use of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is) in treating hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (MBC) have be...
Evaluating time to access opioid treatment for patients with insurance that requires the Safe & Effective Management of Pain prior authorization form vs others [0.03%]
评估需要安全有效镇痛管理事先授权表的保险与其它保险获取阿片类药物治疗的时间差异
Lyndsey P Riffe,Ronald Carico Jr,Sarah Dunaway
Lyndsey P Riffe
Background: In 2016, the Safe & Effective Management of Pain (SEMP) organization created guidelines regarding how to safely and effectively ensure patients were being treated with opioids. Two insurance companies in West ...
Tolebrutinib for secondary progressive multiple sclerosis: A summary from the Institute for Clinical and Economic Review's California Technology Assessment Forum [0.03%]
托莱布鲁丁单抗治疗继发进展型多发性硬化症：临床与经济评审研究所的加利福尼亚技术评估论坛会议概要
Shahariar Mohammed Fahim,Grace A Lin,Brett McQueen et al.
Shahariar Mohammed Fahim et al.
Treatment patterns, health care resource utilization, and costs of heavily treatment-experienced people with HIV in the United States [0.03%]
美国高治疗经验HIV感染者人群的治疗模式、医疗保健资源利用和成本
Samir Gupta,Katherine Cappell,JeanPierre Coaquira Castro et al.
Samir Gupta et al.
Background: Although advancements in antiretroviral therapy (ART) have significantly improved outcomes for people with HIV (PWH), there remains a subset of PWH who are heavily treatment experienced (HTE) and at increased ...
Anna Hung,Sean Dickson
Anna Hung
The price of a prescription drug can be difficult to determine in the United States. Pricing benchmarks are reference points used to determine acquisition costs as drugs are physically moved through the supply chain, to reimburse pharmacies...
Requiring continuous enrollment during follow-up? A call for robust research methods [0.03%]
要求随访期间持续参保？对研究方法的严谨性呼吁
Sujith Ramachandran,Joel Farley,John P Bentley
Sujith Ramachandran
Critical evidence for the evaluation and implementation of managed care strategies relies on researchers examining the health outcomes and costs associated with various pharmacological and nonpharmacological treatments and interventions. Th...
Differences in GLP-1 RA medication adherence across place-based variables in patients with diabetes living in Wisconsin [0.03%]
糖尿病患者GLP-1RA药物依从性的地方差异分析——基于威斯康星州患者的调查
Kara L Gavin,Rabia Amjad,Vaia Makris et al.
Kara L Gavin et al.
Background: Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications are efficacious in improving health outcomes in patients with type 2 diabetes mellitus (T2DM). As demand and costs have increased, questions have...
Primary care physicians prescribe fewer expensive combination medications than dermatologists for acne: A retrospective review [0.03%]
一项回顾性审核：与皮肤科医生相比，全科医师开具的昂贵的联合用药的处方更少用于治疗痤疮
Noah Keime,Oliver Titus,Monika Ziogaite et al.
Noah Keime et al.
Background: Many dermatologic medications are available as expensive combination products, though their lower-cost, generic components are available. Underutilization of these cheaper replacements is common and influenced...
Employee retention for subscribers with and without an obesity diagnosis in self-insured employer health plans: A claims-based analysis [0.03%]
自筹资金的雇主健康计划中肥胖诊断对于员工留存的影响：基于索赔数据的分析
Jessica Naber,Melanie Kuester,Lukasz Chmura et al.
Jessica Naber et al.
Background: Obesity rates in the United States have continued to grow, impacting health care costs and utilization among employer-based commercial insurance coverage. Many employers are now considering offering weight man...
Assessing factor consumption and bleeding outcomes of prophylaxis with 3 commonly prescribed factor IX products for hemophilia B: A retrospective patient medical record analysis in the United States [0.03%]
评估美国B型血友病常用三种凝血因子IX制品的预防给药消耗因素及出血结局：基于患者医疗记录的事后分析
Miguel Escobar,Songkai Yan,Ying Yang et al.
Miguel Escobar et al.
Background: In the United States, rIX-FP, rFIXFc, and rFIX are approved as treatment options for people with hemophilia B (PwHB). Although clinical trials have demonstrated the efficacy and safety of each product, real-wo...